Please login to the form below
ovarian cancer
This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.
Ovarian Cancer Commitment announced to improve patient care
The coalition was announced by ENGAGe, ESGO and AstraZeneca in a call to improve ovarian cancer care. ... The OCC is a coalition, collaborating to focus on improving the experience and survival of women diagnosed with ovarian cancer.
Latest news
-
NICE recommends GSK’s Zejula for patients with ovarian cancer
This extends the time before a patient needs additional chemotherapy. In the UK, it is estimated that at least 41, 000 women are living with ovarian cancer. ... Jack Harris, vice president of Oncology, UK and Ireland at GSK, said: “Recurrent advanced
-
Lynparza significantly delays disease progression as first-line treatment in prostate cancer
Lynparza and other inhibitors of PARP have become established in the treatment of ovarian cancer over the past few years. ... Lynparza is approved in a number of countries in a range of indications, mostly related to ovarian cancer, although it is also
-
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
Small cell lung cancer accounts for 15% of all lung cancers and has a poor prognosis. ... tract cancer, oesophageal cancer, gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial cancer, and other solid tumours.
-
New data advances AstraZeneca’s “revolution in oncology”
In a busy few weeks for AstraZeneca, the company will present data on 14 approved and potential drugs in lung and breast cancer. ... AZ will also present data on Lynparza (olaparib), including data fromthe OReO/ENGOT Ov-38 phase 3b trial testing
-
AZ showcases data for next-generation PARP inhibitor AZD5305
candidate. “Our data at AACR reflect a robust early-stage pipeline, poised to deliver life-changing medicines to patients living with cancer. ... The ongoing study found that Zn-c3 generated five partial responses (PR), with two confirmed PRs in
More from news
Approximately 39 fully matching, plus 185 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
These T cells are then injected back into the bloodstream with the aim of targeting and killing cancer cells. ... Currently the company is conducting a phase 1 trial for advanced ovarian cancer in a dose escalation trial that will treat four separate
-
20 for 2020 – Five pharma companies to watch
That includes potential new approvals for PARP inhibitor Lynparza in prostate and pancreatic cancer to extend its existing use in ovarian and breast cancer. ... in July 2019, which involved 22 plaintiffs who alleged using J&J talc caused them to develop
-
Case study: Ovarian Cancer Action (OCA)
Every rose had a tag with the symptoms of ovarian cancer, Ovarian Cancer Action’s url and #WOCD. ... The charity also lobbied politicians across the UK to support World Ovarian Cancer Day.
-
Leading AstraZeneca’s return to growth in Europe
Reic said the adoption of diagnostics into standard clinical practice has been one of the biggest challenges in Lynparza’s first indication, ovarian cancer – but this must now be replicated in ... First we had ovarian cancer, then breast cancer, and
-
AstraZeneca’s oncology renaissance
Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... People who have BRCA gene mutations have an
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team
There he oversaw the oncology-focused company's launch in the region, as well as the launch and UK reimbursement of its PARP inhibitor in recurrent ovarian cancer.
-
Glycotope appoints Dr Alfredo Zurlo as chief medical officer
He has an exceptionally strong background in oncology both in a clinical setting and within companies developing and marketing treatments for cancer. ... which is currently in phase IIb in ovarian cancer.“.
-
Array appoints Victor Sandor chief medical officer
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
-
VentiRx appoints James Kyle Bryan as chief medical officer
This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian cancer and head and neck cancer.
-
Manish Singh resigns as CEO of ImmunoCellular Therapeutics
We hope that this trial will provide clinical validation of our platform and represent a potential breakthrough treatment for this deadly and intractable cancer," he said. ... We are developing a phase I study with ICT-140 to treat ovarian cancer.”.
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Black community representation in clinical trials
This Black History Month, we discuss the black representation in clinical trials and the effects COVID-19 has had on the black community. Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical
-
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
You only have to think back to the first immunotherapy data in metastatic melanoma or for PARP inhibitors in ovarian cancer to know how compelling such a standard way of presenting
-
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer
Accessed April 2019. 8. Target Ovarian Cancer. Risk and protection factors of ovarian cancer. ... 13. European Medical Journal. The role of PARP inhibitors in ovarian cancer: An emerging picture.
-
What can soaps do for symptoms awareness?
The BBC’s EastEnders and Channel 5’s Neighbours are featuring ovarian cancer storylines. ... There’s the cold public – people who have no knowledge of ovarian cancer.
-
Using storytelling to cut through the chatter in a crowded marketplace
Because enough is enough, too many women are dying too soon from ovarian cancer. ... To join Target Ovarian Cancer’s campaign, visit: www.targetovariancancer.org.uk/TAKEOVAR.
More from PMHub
Approximately 2 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- A creative awakening – how pharma is bringing innovation to the patient journey
- Live Webinar: Streamlining the Drug Development Process to Transform Global Health
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- Pfizer, Mylan move ahead with generics merger and spin-out
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- Roche shares new positive Ocrevus data for MS patients
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
